Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: Is there a case for thoracic cytoreduction

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 27-31

  Perri, Tamar ^a   Ben Baruch, Gilad ^a   Kalfon, Sarit ^a   Beiner, Mario E ^a   Helpman, Limor ^a   Hogen, Liat Ben Davi ^a   Shapira Frommer, Ronnie ^a   Korach, Jacob ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Advanced; Cytoreduction; Ovarian cancer; Recurrence site; Thorax

Indexed keywords

CYCLOPHOSPHAMIDE; GEMCITABINE; PACLITAXEL;

ABDOMINAL CANCER; ABDOMINOPELVIC CYTOREDUCTION; ADULT; AGED; ARTICLE; ASCITES TUMOR; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; HISTOLOGY; HISTORICAL RESEARCH; HUMAN; HUMAN CELL; HYSTERECTOMY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT PLEURA EFFUSION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM TUMOR; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SPLENECTOMY; SURVIVAL RATE; THORACIC CYTOREDUCTION; THORAX DRAINAGE; UNSPECIFIED SIDE EFFECT;

EID: 84885294426     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.093     Document Type: Article

References (32)

1. Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol Jul-Aug 2000;19(1): 11-9.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol Mar 2002;20(5): 1248-59.
3. Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol Sep 2001;82(3): 532-7.
4. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol Jan 2006;107(1): 77-85.
5. RisumS, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography-a prospective study. Gynecol Oncol Feb 2008;108(2): 265-70.
6. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64(1): 4-8.
7. Eitan R, Levine DA, Abu-Rustum N, Sonoda Y, Huh JN, Franklin CC, et al. The clinical significance ofmalignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer Apr 2005;103(7): 1397-401.
8. Mironov O, Ishill NM, Mironov S, Vargas HA, Zheng J, Moskowitz CS, et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology Mar 2011;258(3): 776-84.
9. Lim MC, Lee HS, Jung DC, Choi JY, Seo SS, Park SY. Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery. Ann Surg Oncol Jul 2009;16(7): 1990-6.
10. HuangM, Levine DA, BainsM, Rizk N, Abu-Rustum NR. Intra-thoracic cytoreduction of stage IV peritoneal malignancy: a case series. Gynecol Oncol Dec 2008;111(3): 533-6.
11. JuretzkaMM, Abu-RustumNR, Sonoda Y, Downey RJ, Flores RM, Park BJ, et al. The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol Mar 2007;104(3): 670-4.
12. Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol Jun 2010;21(2): 75-80.
13. Eisenkop SM. Thoracoscopy for themanagement of advanced epithelial ovarian cancer- a preliminary report. Gynecol Oncol Feb 2002;84(2): 315-20.
14. Murthy S. Video-assisted thoracoscopic surgery for the treatment of lung cancer. Cleve Clin J Med May 2012;79(e-Suppl. 1):e-S23-5.
15. Benedet JL, Bender H, Jones III H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet Aug 2000;70(2): 209-62.
16. Munkarah AR, Hallum III AV, Morris M, Burke TW, Levenback C, Atkinson EN, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol Jan 1997;64(1): 13-7.
17. Curtin JP,Malik R, Venkatraman ES, Barakat RR, HoskinsWJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol Jan 1997;64(1): 9-12.
18. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol Jun 2001;81(3): 398-403.
19. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol Mar 1999;72(3): 278-87.
20. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol Jun 2010;17(6): 1642-8.
21. Winter III WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26(1): 83-9.
22. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol Aug 2009;16(8): 2315-20.
23. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, Swisher EM. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol May 2008;109(2): 215-9.
24. Davidson B, Reich R, Trope CG, Wang TL, IeM Shih. New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol Dec 2010;25(12): 1591-609.
25. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-RustumNR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol Nov 2006;103(2): 559-64.
26. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS. The effect ofmaximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol Feb 2008;108(2): 276-81.
27. Eisenkop SM, Friedman RL,Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol May 1998;69(2): 103-8.
28. Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer Mar 2009;115(6): 1234-44.
29. Aletti GD, Podratz KC, Cliby WA, Gostout BS. Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment. Gynecol Oncol Jan 2009;112(1): 22-7.
30. Chi DS, Abu-Rustum NR, Sonoda Y, Chen SW, Flores RM, Downey R, et al. The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol Aug 2004;94(2): 307-11.
31. KlarM, Farthmann J, Bossart M, Stremmel C, Gitsch G, Passlick B, et al. Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer. Gynecol Oncol Sep 2012;126(3): 397-402.
32. Diaz JP, Abu-Rustum NR, Sonoda Y, Downey RJ, Park BJ, Flores RM, et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol 2010;116(3): 483-8.